Polypeptide Group Ag · SIX:PPGN
Polypeptide — 43rd Annual J.P. Morgan Healthcare Conference (January 2025)
14 slides from Polypeptide's conference presentation, Jan 15, 2025
Slide 1: PolyPeptide Group AG
PolyPeptide Group AG Juan José González, CEO 43rd Annual J.P. Morgan Healthcare Conference San Francisco, 15 January 2025 1
Slide 2: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by Group's management in the market in which the Group Alternative Financial Performance Measures (APM) PolyPeptide Group AG (“PolyPeptide” or the “Group”). The operates. While the Group believes that such research and This Presenta
Slide 3: Peptides – one of the most attractive CDMO markets
Peptides – one of the most attractive CDMO markets Peptide drugs in clinical development (Phase I to III)1 Total 321, split by therapeutical area in % • Expect peptide therapeutics market CAGR of around 10% until 2033, driven by GLP-1 commercial launches2 27% 23% • Rich pipeline with over 800 peptid
Slide 4: The metabolic market is evolving rapidly driven by GLP-1
The metabolic market is evolving rapidly driven by GLP-1 Potential benefits beyond metabolic for large patient Continued R&D efforts and progress populations (number of patients)1 • New entrants are advancing next generation Obesity ~650m molecules Type 2 diabetes ~500m Obstructive sleep apnea >900m
Slide 5: PolyPeptide at a glance
PolyPeptide at a glance Torrance (US) Braine-l’Alleud (BE) Malmö (SE) Ambernath (IN) San Diego (US) Strasbourg (FR) • A leader in the peptide CDMO market with multisite network and over 70 years of experience • Track record of >1,000 therapeutic peptides manufactured 5
Slide 6: PolyPeptide is well positioned for accelerated growth
PolyPeptide is well positioned for accelerated growth # of active projects Reported revenue, EUR m1 268 282 320 204 Development 45% Other 64% 16% Oncology 29 For phase III 14% 39% Metabolic 64 Commercial 22% 2023 2021 2023 1 Revenue splits approximative. 6
Slide 7: PolyPeptide's growth strategy to maximize market opportunity
PolyPeptide’s growth strategy to maximize market opportunity Strategy Most innovative peptide CDMO Competitive advantages Innovation Development Modularity Multi-site network Operational / quality excellence Foundation Industrial scale capabilities Talent, culture and ESG 7
Slide 8: Spearheading innovative SPPS manufacturing technologies
Spearheading innovative SPPS manufacturing technologies Large-scale capacity challenges PolyPeptide focus on process intensification Reactor design may influence speed Proprietary technology For technical reasons, there is no linear correlation between Process considerations (incl. automation) and c
Slide 9: 2021-2024 capex investment cycle completed with large-scale SPPS capacity in Braine, Belgium
2021-2024 capex investment cycle completed with large-scale SPPS capacity in Braine, Belgium • 2021-2024 capex investment cycle of EUR ~280 m − Advancing projects across manufacturing network • New large-scale SPPS capacity in Braine-l’Alleud, Belgium, as key milestone to support GLP-1 opportunity −
Slide 10: 2025-2028 capex investment cycle anchored on modular expansion
2025-2028 capex investment cycle anchored on modular expansion • 2025-2028 capex investment cycle targeting 15-20% of revenue − Expansion across manufacturing site network − Large capex projects with customer financing support • Announced doubling SPPS capacity in Malmö, Sweden, with around EUR 100
Slide 11: Guidance for 2024 and mid-term outlook
Guidance for 2024 and mid-term outlook PolyPeptide’s strategy execution is set to create significant value 2023 reported 2024 guidance 2028 outlook EUR 320 million; High single-digit revenue Double 2023 revenue Revenue growth +14% vs 2022 growth (vs 2023 at constant currency rates) EBITDA Margin EBI
Slide 12: Thank you
Thank you PolyPeptide Group AG polypeptide.com 12
Slide 13: Contact and calendar
Contact and calendar Contact Events 2025 Michael Stäheli 09 January 2025 Baader Helvea Swiss Equities Conference, Bad Ragaz Head of Investor Relations & Corporate Communications 10 January 2025 Octavian Swiss Seminar, Davos T: +41 43 502 0580 E: michael.staeheli@polypeptide.com 13-15 January 2025 JP
Slide 14: *|% PolyPeptide
*|% PolyPeptide
PolyPeptide Group — 43rd Annual J.P. Morgan Healthcare Conference (January 2025) on 6ix